Latest from Dana Farber

Jacqueline S. Garcia, MD, discusses results from a phase II trial examining the addition of the BCL-2/BCL-XL inhibitor navitoclax to ruxolitinib in patients with primary or secondary myelofibrosis with acquired resistance to ruxolitinib.
Mary-Ellen Taplin, MD, discusses ongoing research in the prostate cancer treatment paradigm that were presented at the 2020 Genitourinary Cancers Symposium.
Guru P. Sonpavde, MD, discusses advancements made in the field of bladder cancer presented at the 2020 Genitourinary Cancers Symposium.
David P. Steensma, MD, discusses the potential utility of venetoclax in myelodysplastic syndrome.
Toni K. Choueiri, MD, highlights the changes he has observed in clinical practice amidst the COVID-19 pandemic and the unified approach being taken at Dana-Farber Cancer Institute.
Corey S. Cutler, MD, MPH, FRCPC, discusses methods to optimize treatment for patients with acute and chronic graft-versus-host disease.
Reid W. Merryman, MD, discusses the impact of adding high-dose cytarabine to bendamustine and rituximab as an induction regimen for patients with mantle cell lymphoma.
Jacqueline S. Garcia, MD, discusses unmet needs for patients with myelofibrosis who progress on JAK inhibitors.
Publication Bottom Border
Border Publication
x